#United States #Acute Myeloid Leukemia #CAR T-cell Therapy #Aurora #CU Anschutz Institute

CU Anschutz Gates Institute Achieves FDA Clearance for CAR T-Cell Therapy

In a groundbreaking moment for cancer treatment, the University of Colorado Anschutz Gates Institute has received the prestigious Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a chimeric antigen receptor (CAR) T-cell therapy entirely developed on its campus. This marks a significant milestone in the field of hematology and oncology as it’s the first therapy of its kind to receive FDA approval for clinical trials in the United States, specifically targeting adult patients suffering from relapsed or refractory acute myeloid leukemia (AML).

The innovative CAR T-cell therapy is configured to target a crucial protein known as CD64 found on aggressive leukemia cells. This newly engineered treatment presents a hopeful avenue for patients who have run out of standard options, offering a nuanced approach to tackle this challenging disease. This achievement is backed by years of research and development spearheaded by a dedicated team at the CU Anschutz Gates Institute.

Dr. M. Eric Kohler, an assistant professor in pediatrics and hematology, oncology, and bone marrow transplantation at CU Anschutz School of Medicine, is the visionary behind this therapy. Dr. Kohler credited the foundational work led by Craig Jordan's laboratory, who identified CD64 as a marker associated with leukemia cells that avoid standard therapeutic interventions. According to Dr. Kohler, the journey from conceptualization to the first trial on humans exemplifies the collaborative spirit and diverse expertise present on the CU Anschutz campus.

The upcoming Phase 1 clinical trial, set to commence this summer, aims to evaluate the safety, tolerability, and optimal dosage for the CD64 CAR T-cells in adults grappling with this aggressive form of leukemia. Dr. Terry Fry, the executive director of the Gates Institute, quoted, "This FDA clearance encapsulates years of collective efforts from a team deeply committed to bringing cellular therapies into clinical reality." He emphasized the importance of this trial as a stepping stone toward discovering new treatment modalities that could potentially revolutionize therapies for myeloid leukemias, which remain a pressing concern in medical care.

Patient enrollment for the trial is projected to start in June 2026 at the UCHealth University of Colorado Hospital. Alongside this adult-focused initiative, a separate pediatric clinical trial designed for children and adolescents will also take shape later this year under the leadership of Dr. Sanam Shahid at Children's Hospital Colorado. Both trials aspire to furnish novel treatment options for populations with limited resources under current standards of care.

The initiative's significance is underscored by Mathew Angelos, MD, PhD, who oversees the adult clinical trial. Dr. Angelos stated, "This milestone is more than just a scientific achievement; it's a manifestation of the extraordinary commitment and synergy found within our research, clinical, and regulatory teams."

Moreover, the entire process—from laboratory research to clinical application—will be comprehensively facilitated through the Gates Biomanufacturing Facility, ensuring that the breakthrough technology transitions seamlessly to real-world patient care.

The CU Anschutz campus stands out as a leading academic medical establishment, integrating extensive health professional schools and institutions dedicated to transforming science and patient care into actionable, life-changing treatment modalities. Collectively housed within this expansive campus are about 60 specialized research entities and two leading hospitals catering to nearly three million patient encounters annually. With substantial research funding, CU Anschutz is on the frontier of pivotal biomedical research that holds the potential to impact numerous lives.

In conclusion, the FDA clearance of CAR T-cell therapy at the CU Anschutz Gates Institute is a testament to steadfast dedication and an illustrative example of how innovative research translates into tangible benefits for patients, paving the way for revolutionary changes in how we approach treatment for aggressive blood cancers like acute myeloid leukemia.